Antoci J - Search Results

1

Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.

Diokno A, Sand P, Labasky R, Sieber P, Antoci J, Leach G, Atkinson L, Albrecht D. Diokno A, et al. Among authors: antoci j. Int Urol Nephrol. 2002;34(1):43-9. doi: 10.1023/a:1021372426421. Int Urol Nephrol. 2002. PMID: 12549638

2

Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial.

Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, Perez-Marrero R, Jacoby K, Diokno AC, O'Reilly KJ, Griebling TL, Vasavada SP, Yu AS, Frumkin LR; ICOS RTX Study Group (Resiniferatoxin Treatment for Interstitial Cystitis). Payne CK, et al. Among authors: antoci jp. J Urol. 2005 May;173(5):1590-4. doi: 10.1097/01.ju.0000154631.92150.ef. J Urol. 2005. PMID: 15821499 Clinical Trial.

3

Bladder and urethral injuries in patients with pelvic fractures.

Antoci JP, Schiff M Jr. Antoci JP, et al. J Urol. 1982 Jul;128(1):25-6. doi: 10.1016/s0022-5347(17)52734-2. J Urol. 1982. PMID: 7109063 No abstract available.

4

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group. Nitti VW, et al. J Urol. 2017 Feb;197(2S):S216-S223. doi: 10.1016/j.juro.2016.10.109. Epub 2016 Dec 22. J Urol. 2017. PMID: 28012773 Clinical Trial.

5

Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C; 191622-096 Investigators. Nitti VW, et al. J Urol. 2016 Sep;196(3):791-800. doi: 10.1016/j.juro.2016.03.146. Epub 2016 Mar 30. J Urol. 2016. PMID: 27038769 Clinical Trial.

6

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group. Nitti VW, et al. J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14. J Urol. 2013. PMID: 23246476 Clinical Trial.

7

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group. Rovner ES, et al. Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17. Urology. 2008. PMID: 18639327 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters